Amedi.sk
Dovoľujeme si Vás upozorniť, že naša web stránka
je určená iba pre odbornú lekársku verejnosť.
Časopis Gastroenterology for practice – Článok Vedolizumab as a first line biologic for the treatment of ulcerative colitis and Crohn’s disease – the most recent data

Gastroenterology for practice

Reviewed, postgraduate scientific medical journal.
Period 4x per year
ISSN:1336–1473
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Gastroenterology for practice
Gastroenterology for practice
Reviewed, postgraduate scientific medical journal.
Period 4x per year
Predplatné
Téma: Overview works

Vedolizumab as a first line biologic for the treatment of ulcerative colitis and Crohn’s disease - the most recent data

Laura Gombošová

Inflammatory bowel diseases are immune mediated inflammatory disorders of the digestive tract, induced and maintained by T lymphocytes dysregulation, with genetic background and dysbiosis of the gut microbiota with environment influence. Crohn’s disease frequently causes structural damage to the intestinal tract resulting in complications of stricture, fistula and abscess formation, loss of function. Patients require surgical therapy in addition to medication. Vedolizumab is a gut-selective monoclonal antibody against ɑ4β7 integrins with inhibiting vascular adhesion and migration of lymphocytes to intestinal mucosa. It is indicated for therapy of moderate to severe Crohn’s disease and ulcerative colitis.
In comparison with antiTNF infliximab, vedolizumab has similar effectivity with lower incidence of infectious adverse events and higher therapy persistence. Head to head comparing trial VARSITY (comparison of vedolizumab and adalimumab) demonstrates superior clinical and endoscopic efficacy of vedolizumab for the treatment of moderately to severely active ulcerative colitis, with early clinical response in week 14. Trial LOVE-CD and EVOLVE demonstrate higher rate of endoscopic response and remission in bio-naive patients. Bio-naive patients with Crohn’s disease and ulcerative colitis treated with vedolizumab achieved higher efficacy in comparison with antiTNF exposed and would be suitable for the first line biological en_option.

Crohns’s disease, ulcerative colitis, vedolizumab, clinical remission, endoscopic healing
Gastroenterol. prax 2019; 18 (3): 130-135

Ročník 2019  Témy časopisu Gastroenterology for practice 3 / 2019

THEME SECTION

Eduard Veseliny, Martin Janičko, Peter Jarčuška
Adam Vašura, Petr Dítě, Tomáš Kupka, Martin Blaho, Pavel Svoboda, Vladimír Hrabovský
Martin Blaho, Petr Dítě, Ivo Novotný, Bohuslav Kianička
Anton Vavrečka, Michelle Swekla
Petr Dítě, Lumír Kunovský, Martin Blaho, Jana Dvořáčková, Martina Bojková, Magdalena Uvírová

Overview works

Laura Gombošová
Tomáš Šálek
Silvia Timková, Martina Kyjovská-Čičvaková, Eugen Ďurovič
2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4 3 2 1
4
Nie sú dostupné žiadne voľne dostupné články
CHAIRMAN OF THE EDITORIAL BOARD
prof. MUDr. Rudolf Hyrdel, CSc.

MEMBERS OF THE EDITORIAL BOARD
doc. MUDr. Marian Bátovský, CSc., mim. prof. SZU
prof. MUDr. Juraj Bober, CSc.
MUDr. Ivan Bunganič
prof. MUDr. Petr Dítě, DrSc.
doc. MUDr. Martin Huorka, CSc.
doc. MUDr. Peter Makovník, CSc.
MUDr. Juraj Májek, PhD.
prof. MUDr. Peter Mlkvý, CSc.
MUDr. Tomáš Šálek
MUDr. Renata Szépeová, PhD.
prof. MUDr. Anton Vavrečka, CSc.
MUDr. Mária Zakuciová

EDITOR-IN-CHIEF
Ing. Danica Paulenová
e-mail: paulenova@amedi.sk

GRAPHIC LAYOUT AND TYPESETTING
Lucia Vecseiová
e-mail: dtp@amedi.sk 

MARKETING MANAGER
Ing. Dana Lakotová
mobil: 0903 224 625
e-mail: marketing@amedi.sk

ECONOMY AND SUBSCRIPTIONS
Ing. Mária Štecková
telefón: 02/55 64 72 48
mobil: 0911 117 949
e-mail: ekonom@amedi.sk

PROFESSIONAL PROOFREADING
doc. MUDr. Soňa Kiňová, PhD.

LANGUAGE PROOFREADING
Mgr. Eva Doktorová

PROOFREADING OF ENGLISH TEXTS
Mgr. Jana Bábelová
SECTIONS

SURVEY WORKS
The latest knowledge on disease and disease groups aetiology, pathogenesis, diagnoses and therapy.
Maximum size is 8 pages (font size 12, line spacing 1.5) with maximum five pictures (graphs). In case of more extensive theme elaboration it is possible to divide the paper to several parts after agreement with editorial office. Write the article with focus on its practical use for gastroenerologists and specialists from other disciplines interested in gastroenterology.

CASE STUDY
Maximum extent is 7 pages. Structuring: summary, introduction, case study, discussion, conclusion, bibliography.

DIAGNOSTIC AND THERAPEUTICAL ALGORITHMS
Diagnosis and therapy processed into tables and schemes, with minimum text, with emphasis on conciseness and clarity.

REVIEWS FROM LITERATURE
News from foreign press, news in the field of diagnoses, therapies and other professional information, maximum extent is 2 pages.

MISCELLANEOUS
Reactions to articles, information on professional events, new books, reviews, conference reports, invitations and so on. Abstract written in Slovak or Czech from scientific work published here or abroad, not older than 1 year. Maximum extent is 1 page. Write the title of the paper in Slovak/Czech, authors, workplace, then title of the paper in English with full citation. Appropriate is to explain basic terms.


MANUSCRIPT ELABORATION

Write the paper on computer in any common text editor.
- write full length of lines (do not use ENTER at the end of a line)
- do not arrange the text into columns - do not do page make-up, tables put at the end of the paper.
- distinguish precisely numbers 1, 0 and letters l, O
- use always parentheses ( )
- explain abbreviations always when first used


MANUSCRIPT REQUIREMENTS

1. An accurate paper title, names and surnames of all authors including titles, authors` workplace. The first author address including the phone number, fax and e-mail address.
2. Summary - concise content summary in the extent maximum 10 lines (only at overview papers, case studies). Write in 1st or 3rd person singular or plural (unify according the type of an article).
3. Key words - in the extent of 3-6 (only for overview papers and case studies).
4. English translation: paper title, summary, key words (only at overview papers and case studies)
5. Text
If you insert pictures into a document, send also their original files in "jpg" format, create graphs in Excel and send also their original files. If you send photo documentation via post office, please, send just high-class originals. Mark each original by a number, under which it is mentioned in the text. Write in 1st or 3rd person singular or plural (unify according the type of an article).
6. Bibliography
Citations are numbered chronologically in bold, references in the text are stated by the number of citations in parentheses. Use maximum 20 citations.

Examples of citations:
1. Vaughan TL, Davis S, Kristal A, et al. Obesity, alcohol and tobacco risk factors for cancers of esophagus and gastric cardia :adenocarcinoma versus squamous cell carcinoma Cancer Epidemiol Biomarkers Prev 1995; 4: 85-92.
2. Gao YT, McLaughlin JT, Gridley T, et al. Risk factors for esophageal cancer in Shanghai, China. Role of diet and nutrients. Int J Cancer 1994; 58: 197-202.
3. Shaheen NJ, Crosby NA, Bozymski EM, et al. Is there publication bias in the reporting cancer risk in Barrett´ esophagus? Gastroenterology 2000; 119: 333-338.

Do not use dots after first names in citations. Do not use colon but dot after names of authors. Use semi-colon after the year of publishing, colon is before pages. If an author is one, two or three - it is necessary to state all. If there are more than three authors it is necessary to write first three and "et all", in Slovak and Czech citations "a spol."


AUTODIDACTIC TEST

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are reviewed.

Origination of pigment stones is related to:
a. acute haemolysis
b. chronic haemolysis
c. hypercalcaemia
d. hyperlipoproteinaemia

The editorial board reserves the right to make small stylistic changes in the paper. If it is necessary to shorten the paper, the consent of the author will be required. All articles are double reviewed.

All published papers are paid.

Due to practical focus of the journal we would like to ask you to write the paper comprehensively, with emphasis on practical use of provided information in out-patient practice of gastroenterologists and related specialisations.

Send contributions in the e-mail to the address: paulenova@amedi.sk
Period 4x per year
ISSN:1336–1473
The journal is indexed in the Slovak National Bibliography, Bibliographiia Medica Slovaca (BMS) and listed to citation database CiBaMed. All articles are reviewed. The publisher does not bear any responsibility for data and opinions of particular authors of the articles or advertisements. The articles on grey pages are company promotions or non reviewed information, an author is responsible for the content. Any reproduction of the content is allowed only with direct consent of the editorial office.
Predplatné
Gastroenterology for practice
Gastroenterology for practice
Reviewed, postgraduate scientific medical journal.
Period 4x per year
Predplatné